ArticleFrontiers in endocrinology2026
Analysis of immune and autophagy-related genes and their regulatory mechanisms in osteoporosis patients post-menopause.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postmenopausal osteoporosis (PMO) is a prevalent metabolic bone disease wherein immune dysregulation and autophagy are critically involved. This study aimed to identify key genes linking immune cells and autophagy in PMO and construct a diagnostic model. Methods: Autophagy-immune-related differentially expressed genes (DEGs) were identified by integrating limma analysis, WGCNA module genes, and autophagy-related genes (ARGs). Hub genes were screened via protein-protein interaction (PPI) network and statistical tests. A diagnostic model was built and validated. Functional enrichment (GSEA) and immune infiltration analysis (GSVA) were performed. Regulatory networks involving transcription factors (TFs) and microRNAs (miRNAs) were constructed. Drug prediction and single-cell RNA sequencing (scRNA-seq) analyses were conducted. An ovariectomized (OVX) mouse model was established to assess bone mineral density, serum biomarkers, and hub gene expression via RT-qPCR. Results: Three hub genes (CDK2, DDIT3, MAPK8) were identified. The diagnostic model exhibited high predictive accuracy (AUC = 0.91). GSEA indicated CDK2 and DDIT3 were associated with ligand-receptor interaction pathways. Hub genes correlated significantly with altered immune cell infiltration. Regulatory networks included multiple TFs and miRNAs. Drug prediction identified potential therapeutics targeting each hub gene. scRNA-seq highlighted bone marrow mesenchymal stem cells (BM MSCs) as a key site, with pseudotemporal analysis revealing dynamic hub gene expression during differentiation. Conclusion: An immune-autophagy-related diagnostic model based on DDIT3 and MAPK8 was developed and validated, offering new insights into PMO evaluation and therapeutic strategy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.